Add like
Add dislike
Add to saved papers

Fasting plasma glucose is not sufficient to detect ongoing glucose intolerance after pregnancy complicated by gestational diabetes.

AIMS: Women who develop diabetes during pregnancy are at significant risk of developing Type 2 diabetes later in life, and "should be offered blood glucose testing ... to exclude persisting hyperglycaemia" after delivery. New UK guidelines now recommend that this is done by measurement of fasting blood glucose, rather than an oral glucose tolerance test (OGTT). Our study aims to establish whether assessment by fasting blood glucose gives equivalent results to an OGTT.

METHODS: Retrospective data were obtained from four centres in the West Midlands, UK, who performed a postnatal OGTT on 470 women during a 12-month period. All centres used a 75 g, 2-h protocol.

RESULTS: 28 of 470 (6.0%) women had diabetes mellitus after testing of fasting plasma glucose. After OGTT, 70 women (14.9%) were found to have impaired glucose tolerance (IGT), and 10 further cases of diabetes were detected (overall prevalence of DM 8.1%). Of the 400 women with normal fasting plasma glucose. After OGTT, 70 women (14.9%) were found to have impaired glucose tolerance (IGT), and 10 further cases of diabetes were detected (overall prevalence of DM 8.1%). Of the 400 women with normal fasting plasma glucose (< or = 6.0 mmol/l), 55 were found to have impaired glucose tolerance and 4 had overt diabetes. In all, 26% of women with diabetes were missed by FPG.

CONCLUSION: Fasting plasma glucose alone does not allow detection of IGT, and misses a substantial proportion of women with Type 2 diabetes. Recognition of ongoing IGT or DM is important in identifying women who may benefit from lifestyle modification, and who may need early intervention in subsequent pregnancies. Our results suggest that OGTT should be the investigation of choice in the postnatal assessment of women who have had GDM.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app